Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1.

Vijayakrishnan J, Kumar R, Henrion MY, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS.

Leukemia. 2017 Mar;31(3):573-579. doi: 10.1038/leu.2016.271. Epub 2016 Oct 3.

2.

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.

Vallarelli AF, Rachakonda PS, André J, Heidenreich B, Riffaud L, Bensussan A, Kumar R, Dumaz N.

Oncotarget. 2016 Aug 16;7(33):53127-53136. doi: 10.18632/oncotarget.10634.

3.

Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.

Xie H, Rachakonda PS, Heidenreich B, Nagore E, Sucker A, Hemminki K, Schadendorf D, Kumar R.

Oncotarget. 2016 Mar 29;7(13):16490-504. doi: 10.18632/oncotarget.7503.

4.

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.

Willmes C, Kumar R, Becker JC, Fried I, Rachakonda PS, Poppe LM, Hesbacher S, Schadendorf D, Sucker A, Schrama D, Ugurel S.

Oncotarget. 2016 Mar 1;7(9):10117-32. doi: 10.18632/oncotarget.6956.

5.

Frequent DPH3 promoter mutations in skin cancers.

Denisova E, Heidenreich B, Nagore E, Rachakonda PS, Hosen I, Akrap I, Traves V, García-Casado Z, López-Guerrero JA, Requena C, Sanmartin O, Serra-Guillén C, Llombart B, Guillén C, Ferrando J, Gimeno E, Nordheim A, Hemminki K, Kumar R.

Oncotarget. 2015 Nov 3;6(34):35922-30. doi: 10.18632/oncotarget.5771.

6.

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.

Laugier F, Finet-Benyair A, André J, Rachakonda PS, Kumar R, Bensussan A, Dumaz N.

Oncotarget. 2015 Sep 29;6(29):28120-31. doi: 10.18632/oncotarget.4866.

7.

Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.

Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, Hemminki K, Kumar R.

Int J Cancer. 2015 Oct 1;137(7):1621-9. doi: 10.1002/ijc.29526. Epub 2015 Apr 7.

8.

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.

Heidenreich B, Rachakonda PS, Hosen I, Volz F, Hemminki K, Weyerbrock A, Kumar R.

Oncotarget. 2015 Apr 30;6(12):10617-33.

9.

TERT promoter mutations in clear cell renal cell carcinoma.

Hosen I, Rachakonda PS, Heidenreich B, Sitaram RT, Ljungberg B, Roos G, Hemminki K, Kumar R.

Int J Cancer. 2015 May 15;136(10):2448-52. doi: 10.1002/ijc.29279. Epub 2014 Oct 30.

10.

TERT promoter mutations in cancer development.

Heidenreich B, Rachakonda PS, Hemminki K, Kumar R.

Curr Opin Genet Dev. 2014 Feb;24:30-7. doi: 10.1016/j.gde.2013.11.005. Epub 2013 Dec 20. Review.

PMID:
24657534
11.

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R.

Nat Commun. 2014 Feb 26;5:3401. doi: 10.1038/ncomms4401.

PMID:
24569790
12.

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.

Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17426-31. doi: 10.1073/pnas.1310522110. Epub 2013 Oct 7.

13.

Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development.

Dutruel C, Bergmann F, Rooman I, Zucknick M, Weichenhan D, Geiselhart L, Kaffenberger T, Rachakonda PS, Bauer A, Giese N, Hong C, Xie H, Costello JF, Hoheisel J, Kumar R, Rehli M, Schirmacher P, Werner J, Plass C, Popanda O, Schmezer P.

Oncogene. 2014 Jun 26;33(26):3401-10. doi: 10.1038/onc.2013.312. Epub 2013 Aug 5.

PMID:
23912455
14.

Variants at the 9p21 locus and melanoma risk.

Maccioni L, Rachakonda PS, Bermejo JL, Planelles D, Requena C, Hemminki K, Nagore E, Kumar R.

BMC Cancer. 2013 Jul 2;13:325. doi: 10.1186/1471-2407-13-325.

15.

Somatic mutations in exocrine pancreatic tumors: association with patient survival.

Rachakonda PS, Bauer AS, Xie H, Campa D, Rizzato C, Canzian F, Beghelli S, Greenhalf W, Costello E, Schanne M, Heller A, Scarpa A, Neoptolemos JP, Werner J, Büchler M, Hoheisel JD, Hemminki K, Giese N, Kumar R.

PLoS One. 2013;8(4):e60870. doi: 10.1371/journal.pone.0060870. Epub 2013 Apr 2.

16.

TERT promoter mutations in familial and sporadic melanoma.

Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R.

Science. 2013 Feb 22;339(6122):959-61. doi: 10.1126/science.1230062. Epub 2013 Jan 24.

17.

Variants at chromosome 20 (ASIP locus) and melanoma risk.

Maccioni L, Rachakonda PS, Scherer D, Bermejo JL, Planelles D, Requena C, Hemminki K, Nagore E, Kumar R.

Int J Cancer. 2013 Jan 1;132(1):42-54. doi: 10.1002/ijc.27648. Epub 2012 Jun 13.

18.

Integrin genes and susceptibility to human melanoma.

Lenci RE, Rachakonda PS, Kubarenko AV, Weber AN, Brandt A, Gast A, Sucker A, Hemminki K, Schadendorf D, Kumar R.

Mutagenesis. 2012 May;27(3):367-73. doi: 10.1093/mutage/ger090. Epub 2011 Dec 20.

PMID:
22189006
19.

Pancreatic cancer susceptibility loci and their role in survival.

Rizzato C, Campa D, Giese N, Werner J, Rachakonda PS, Kumar R, Schanné M, Greenhalf W, Costello E, Khaw KT, Key TJ, Siddiq A, Lorenzo-Bermejo J, Burwinkel B, Neoptolemos JP, Büchler MW, Hoheisel JD, Bauer A, Canzian F.

PLoS One. 2011;6(11):e27921. doi: 10.1371/journal.pone.0027921. Epub 2011 Nov 18.

20.

DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.

Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R.

Ann Surg Oncol. 2011 Sep;18(9):2688-98. doi: 10.1245/s10434-011-1601-y. Epub 2011 Feb 24.

PMID:
21347786
21.

Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.

Scherer D, Rachakonda PS, Angelini S, Mehnert F, Sucker A, Egberts F, Hauschild A, Hemminki K, Schadendorf D, Kumar R.

J Invest Dermatol. 2010 Dec;130(12):2844-8. doi: 10.1038/jid.2010.242. Epub 2010 Aug 19. No abstract available.

22.

Co-expression of insulin-like growth factor-1 and interleukin-4 in an in vitro inflammatory model.

Manning K, Rachakonda PS, Rai MF, Schmidt MF.

Cytokine. 2010 Jun;50(3):297-305. doi: 10.1016/j.cyto.2010.01.010. Epub 2010 Feb 25.

PMID:
20188584
23.

Molecular and phenotypic modulations of primary and immortalized canine chondrocytes in different culture systems.

Rai MF, Rachakonda PS, Manning K, Palissa C, Sittinger M, Ringe J, Schmidt MF.

Res Vet Sci. 2009 Dec;87(3):399-407. doi: 10.1016/j.rvsc.2009.04.008. Epub 2009 May 12.

PMID:
19439332
24.

Expression of canine interleukin-4 in canine chondrocytes inhibits inflammatory cascade through STAT6.

Rachakonda PS, Rai MF, Manning K, Schmidt MF.

Cytokine. 2008 Oct;44(1):179-84. doi: 10.1016/j.cyto.2008.07.470. Epub 2008 Sep 11.

PMID:
18789870
25.

Energetics of the loop-to-helix transition leading to the coiled-coil structure of influenza virus hemagglutinin HA2 subunits.

Huang Q, Korte T, Rachakonda PS, Knapp EW, Herrmann A.

Proteins. 2009 Feb 1;74(2):291-303. doi: 10.1002/prot.22157.

PMID:
18618705
26.

Application of inflammation-responsive promoter for an in vitro arthritis model.

Rachakonda PS, Rai MF, Schmidt MF.

Arthritis Rheum. 2008 Jul;58(7):2088-97. doi: 10.1002/art.23598.

27.

Quantification of cytokines and inflammatory mediators in a three-dimensional model of inflammatory arthritis.

Rai MF, Rachakonda PS, Manning K, Vorwerk B, Brunnberg L, Kohn B, Schmidt MF.

Cytokine. 2008 Apr;42(1):8-17. doi: 10.1016/j.cyto.2008.02.004. Epub 2008 Mar 17.

PMID:
18343681
28.

The relevance of salt bridges for the stability of the influenza virus hemagglutinin.

Rachakonda PS, Veit M, Korte T, Ludwig K, Böttcher C, Huang Q, Schmidt MF, Herrmann A.

FASEB J. 2007 Apr;21(4):995-1002. Epub 2007 Jan 11.

PMID:
17218542
29.

Conformational change of influenza virus hemagglutinin is sensitive to ionic concentration.

Korte T, Ludwig K, Huang Q, Rachakonda PS, Herrmann A.

Eur Biophys J. 2007 Apr;36(4-5):327-35. Epub 2007 Jan 9.

PMID:
17211621

Supplemental Content

Loading ...
Support Center